Volume 10, Number 12—December 2004
Dispatch
Genome Sequence and Attenuating Mutations in West Nile Virus Isolate from Mexico
David W.C. Beasley*
, C. Todd Davis*, Jose Estrada-Franco*, Roberto Navarro-Lopez†, Arturo Campomanes-Cortes†, Robert B. Tesh*, Nikos Vasilakis*, and Alan D.T. Barrett*
, C. Todd Davis*, Jose Estrada-Franco*, Roberto Navarro-Lopez†, Arturo Campomanes-Cortes†, Robert B. Tesh*, Nikos Vasilakis*, and Alan D.T. Barrett*
Table 2
Neuroinvasiveness and neurovirulence of TM-171 Mex03 parental isolate and plaque-purified variants after injection into 3- to 4-week-old female NIH Swiss micea
| Virus | E154-156 sequence | i.p. LD50 (PFU) | i.p. AST ± SD (d)b | i.c. LD50 (PFU) | i.c. AST ± SD (d)b |
|---|---|---|---|---|---|
| TM171-03 | NYP/S | 1.3 | 7.9 ± 0.7 | 0.8 | 6.2 ± 1.8 |
| TM171-03-pp1 | NYP | >1000 | NA | 32 | 6.0 ± 0.9 |
| TM171-03-pp2 | NYP | >1000 | NA | 25 | 6.7 ± 1.7 |
| TM171-03-pp5 | NYS | 2.0 | 9.0 ± 1.4 | 2.0 | 7.4 ± 1.2 |
| TM171-03-pp6 | NYS | 2.0 | 8.5 ± 1.7 | 1.3 | 7.4 ± 0.9 |
aNIH, National Institutes of Health; AST, average survival time; i.p., intraperitoneal; i.c., intracranial; LD50, 50% lethal dose; SD, standard deviation; NA, not applicable.
bAverage survival time ± SD was calculated for all animals that died following inoculation with 1,000 - 0.1 PFU doses of indicated virus.
Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.